<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075996</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-10280</org_study_id>
    <nct_id>NCT02075996</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With Pomalidomide (Imnovid®)</brief_title>
  <acronym>Poseidon</acronym>
  <official_title>Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional study is to collect data on the efficiency and safety
      of pomalidomide in combination with dexamethasone in the routine application
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Discontinuation (TTD)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse reaction profile</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary malignancies</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>long term safety is focused on secondary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall Survival (OS)</measure>
    <time_frame>6 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative dose intensity of pomalidomide and dexamethasone</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess changes in myeloma-related quality of life</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>explore additional supportive therapies</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To explore additional supportive therapies used on this patient population (e.g. G-CSF, antibiotics, DVT prophylaxis)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide following lenalidomide</arm_group_label>
    <description>75 patients with pomalidomide directly following lenalidomide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide following other therapy</arm_group_label>
    <description>75 patients with pomalidomide following any other prior therapy. This includes 	lenalidomide in earlier lines than the most recent line.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with relapsing or refractory multiple myeloma previously treated with at
        least two prior lines of therapy, including bortezomib and lenalidomide who have
        progressed under their last therapy regimen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed or refractory multiple myeloma Patients must have received at
             least two prior lines of treatment (induction therapy followed by stem cell
             transplantation ± maintenance therapy is considered one prior therapy) and must have
             progressed under the most recent therapy regimen

          -  Adult male and female patients (at least 18 years with no upper age limit)

          -  Written informed consent to data collection and pseudonymized data transfer

          -  The conditions of the Pregnancy Prevention Programme must be fulfilled for all
             patients unless there is reliable evidence that the patient does not have
             childbearing potential (see summary of product characteristics Imnovid®)

          -  Other criteria according to summary of product characteristics Imnovid®

        Exclusion Criteria:

          -  Missing patient's informed consent

          -  Pregnant or breast-feeding women

          -  Male patients, not capable of complying the required preventive measures (see
             summary of product characteristics Imnovid®)

          -  Other criteria according to summary of product characteristics Imnovid®
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Dechow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>practice based oncology office Ravensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Teichmann, PhD</last_name>
    <phone>+4976115242</phone>
    <phone_ext>13</phone_ext>
    <email>beate.teichmann@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>iOMEDICO AG</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Teichmann, PhD</last_name>
      <phone>076115242</phone>
      <phone_ext>13</phone_ext>
      <email>beate.teichmann@iomedico.com</email>
    </contact>
    <investigator>
      <last_name>Tobias Dechow, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
